Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will publish the (a) name and (b) proportion of the £50 million funding for research into long-covid of each study that will be supported by that funding.
The following table shows the research projects funded through research calls for the long term effects of COVID-19 and by the National Institute for Health Research through its funding streams, with the proportion of the £50.97 million investment received.
Project description | Percentage of investment |
REACT-Long COVID (REACT-LC) programme | 10.7% |
Non-hospitalised Children & young people (CYP) with Long Covid (The CLoCk Study) | 3.6% |
Therapies for Long COVID in non-hospitalised individuals: From symptoms, patient reported outcomes and immunology to targeted therapies (The TLC Study) | 4.4% |
Characterisation, determinants, mechanisms and consequences of the long-term effects of COVID-19: providing the evidence base for health care services | 18.8% |
Development of a robust T cell assay to retrospectively diagnose SARS-CoV-2 infection and IFN-γ release assay as diagnostic and monitoring assay in Long COVID patients | 0.7% |
Explaining why long COVID patients experience breathlessness and a reduced ability to exercise | 3.5% |
The immunologic and virologic determinants of long COVID | 1.5% |
Understanding and treating ‘brain fog’ | 2.4% |
Immune analysis of Long COVID to inform rational choices in diagnostic testing and therapeutics | 1.1% |
Understanding and using family experiences of managing long COVID to support self- care and timely access to services | 1.1% |
Quality-of-life in patients with long COVID: harnessing the scale of big data to quantify the health and economic costs | 1.3% |
Optimising standards of care for long COVID in hospitals, doctors’ surgeries and at home | 6.7% |
Using Activity Tracking and Just-In-Time Messaging to Improve Adaptive Pacing: A Pragmatic Randomised Control Trial | 0.6% |
ReDIRECT: Remote Diet Intervention to Reduce long Covid symptoms Trial | 2.0% |
Co-designing personalised self-management support for people with Long Covid | 2.2% |
Percutaneous Auricular Nerve Stimulation for Treating Post-COVID Fatigue (PAuSing-Post-COVID Fatigue) | 1.3% |
Developing and testing the best ways to diagnose, treat and provide rehabilitation for people with long COVID | 13.3% |
Impact of COVID-19 vaccination on preventing long COVID: a population-based cohort study using linked NHS data | 0.4% |
Long COVID Core Outcome Set (LC-COS) project | 0.3% |
UK evaluation of NHS support post-hospitalisation for COVID19 to inform service development and achieve holistic, integrated, equitable and cost-effective services | 1.0% |
Post-hospital COVID-19 Study (PHOSP-COVID) | 16.5% |
HEAL-COVID - a study to develop treatments for COVID-19 that reduce the longer-term death and disability | 6.9% |